Mouse study illustrates the virus' bold attack on the immune system
SUNDAY, Oct. 20 (HealthDay News) -- If you've ever wondered how the flu virus succeeds at infecting so many people, a new study of mice may offer some insight.
The flu actually targets cells of the immune system that are best able to disarm the virus, according to the study. These first responders, known as memory B cells, produce antibodies that can bind to the virus and neutralize it. These cells also reside in the lung where they can protect against re-exposure to the virus.
Researchers found, however, that the flu virus attacks these memory B cells first to disrupt antibody production, allowing it to replicate more efficiently and prevent the immune system from mounting a second defense.
"We can now add this to the growing list of ways that the flu virus has to establish infection," study co-author Joseph Ashour, a postdoctoral researcher at the Whitehead Institute for Biomedical Research, said in an institute news release.
Memory B cells, which have virus-specific receptors, are difficult to isolate. To address this issue, the researchers attached a fluorescent label to the flu virus, which allowed them to identify flu-specific B cells. They then used a cloning technique to create a line of mice with virus-specific B cells and cell receptors.
The study authors suggested that the infectious process of the flu is probably used by other viruses as well. "We can now make highly effective immunological models for a variety of pathogens," Dougan concluded. "This is actually a perfect model for studying memory immune cells."
Scientists note, however, that research with animals often fails to produce similar results in humans.
"This is research that could help with rational vaccine design, leading to more effective vaccines for seasonal flu," Ashour said. "It might even suggest novel strategies for conferring immunity."
The study was recently published in the journal Nature.
SOURCE: Whitehead Institute for Biomedical Research, news release, Oct. 20, 2013
Be the first to comment on this!
Personal Subscriber? Sign In
Note: Please enter a display name. Your email address will not be publically displayed